Biomarkers of response and resistance to antiangiogenic therapy.

Biomarkers of response and resistance to antiangiogenic therapy.
复制标题

DOI:
10.1038/nrclinonc.2009.63
复制
发表时间:
2009-06
期刊:
Nature reviews. Clinical oncology
影响因子:
--
通讯作者:
--
中科院分区:
其他
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

目前没有经过验证的生物标志物(或生物标志物)可用于适当选择癌症患者进行抗血管生成治疗。也没有生物标志物识别逃逸途径,应该针对肿瘤发展耐药性后,一个给定的抗血管生成剂。最近完成的I-III期研究中出现了许多潜在的全身、循环、组织和成像生物标志物。其中一些在基线时测量(例如VEGF多态性),其他在治疗期间测量(例如高血压,MRI测量的Ktranss,循环血管生成分子或胶原IV),并且所有都是基于机制的。这些生物标志物中的一些可能是药效学的(例如,循环VEGF、胎盘生长因子的增加),而其他生物标志物具有预测临床获益或识别逃逸途径的潜力(例如,基质细胞衍生因子1α、白细胞介素-6)。大多数生物标志物是疾病和/或药剂特异性的,并且所有这些都需要进行前瞻性验证。我们讨论了目前建立抗血管生成治疗生物标志物的挑战,定义了全身、循环、组织和成像生物标志物及其优缺点,并评论了未来验证抗血管生成治疗生物标志物的机会。
No validated biological markers (or biomarkers) currently exist for appropriately selecting patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape pathways that should be targeted after tumors develop resistance to a given antiangiogenic agent. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I–III studies. Some of these are measured at baseline (for example VEGF polymorphisms), others are measured during treatment (such as hypertension, MRI-measured Ktrans, circulating angiogenic molecules or collagen IV), and all are mechanistically based. Some of these biomarkers might be pharmacodynamic (for example, increase in circulating VEGF, placental growth factor) while others have potential for predicting clinical benefit or identifying the escape pathways (for example, stromal-cell-derived factor 1α, interleukin-6). Most biomarkers are disease and/or agent specific and all of them need to be validated prospectively. We discuss the current challenges in establishing biomarkers of antiangiogenic therapy, define systemic, circulating, tissue and imaging biomarkers and their advantages and disadvantages, and comment on the future opportunities for validating biomarkers of antiangiogenic therapy.
DOI: 10.1016/j.cell.2007.08.038
发表时间: 2007-11-02
期刊: CELL
影响因子: 64.5
作者:
Fischer, Christian;Jonckx, Bart;Carmeliet, Peter
通讯作者: Carmeliet, Peter
DOI: 10.1073/pnas.0708148104
发表时间: 2007-10-23
影响因子: 11.1
作者:
Ebos, John M. L.;Lee, Christina R.;Kerbel, Robert S.
通讯作者: Kerbel, Robert S.
DOI: 10.1200/jco.2006.09.6305
发表时间: 2007-04-20
影响因子: 45.3
作者:
Giantonio, Bruce J.;Catalano, Paul J.;Benson, Al B., III
通讯作者: Benson, Al B., III
DOI: 10.1016/j.ccr.2005.09.005
发表时间: 2005-10-01
期刊: CANCER CELL
影响因子: 50.3
作者:
Casanovas, O;Hicklin, DJ;Hanahan, D
通讯作者: Hanahan, D
DOI: 10.1200/jco.2006.10.5825
发表时间: 2007-10-20
影响因子: 45.3
作者:
Chen, Wei;Delaloye, Sibylle;Cloughesy, Timothy
通讯作者: Cloughesy, Timothy